Squalene Epoxidase Metabolic Dependency Is a Targetable Vulnerability in Castration-Resistant Prostate Cancer

被引:28
|
作者
Xun Shangguan [1 ]
Ma, Zehua [2 ]
Yu, Minghao [1 ]
Ding, Jie [1 ]
Xue, Wei [2 ]
Qi, Jun [1 ]
机构
[1] Shanghai Jiao Tong Univ, Xinhua Hosp, Dept Urol, Sch Med, Shanghai 200092, Peoples R China
[2] Shanghai Jiao Tong Univ, Renji Hosp, Sch Med, Dept Urol, Shanghai, Peoples R China
关键词
CHOLESTEROL-SYNTHESIS; ANDROGEN RECEPTOR; MONOOXYGENASE; INHIBITION; MECHANISMS; PATHWAY; PTEN; PROGRESSION; THERAPIES; ENZYME;
D O I
10.1158/0008-5472.CAN-21-3822
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Considering the dismal prognosis of castration-resistant prostate cancer (CRPC), it is critical to identify novel therapeutic targets in this disease. Malignant cells have metabolic dependencies distinct from their healthy counterparts, resulting in therapeutic vulnerabilities. Although PTEN and TP53 are the most frequently comutated or codeleted driver genes in lethal CRPC, the metabolic dependencies underlying PTEN/p53 deficiency-driven CRPC for therapeutic intervention remain largely elusive. In this study, PTEN/p53 deficient tumors were determined to be reliant on cholesterol metabolism. Moreover, PTEN/p53 deficiency transcriptionally upregulated squalene epoxidase (SQLE) via activation of sterol regulatory element-binding protein 2 (SREBP2). In addition, PTEN deficiency enhanced the protein stability of SQLE by inhibiting the PI3K/Akt/GSK3 beta-mediated proteasomal pathway. Consequently, SQLE increased cholesterol biosynthesis to facilitate tumor cell growth and survival. Pharmacologic blockade of SQLE with FR194738 profoundly suppressed the invasive program of CRPC. Collectively, these results demonstrate a synergistic relationship between SQLE and PTEN/p53 deficiency in CRPC development and progression. Therefore, pharmacologic interventions targeting SQLE may hold promise for the treatment of patients with CRPC. Significance: This study reveals PTEN and p53 deficiency confers a dependence on SQLE-mediated cholesterol metabolism, providing insights for new therapeutic strategies for treating castration-resistant prostate cancer.
引用
收藏
页码:3032 / 3044
页数:13
相关论文
共 50 条
  • [11] Castration-resistant prostate cancer (CRPC)
    Loidl, W.
    Luger, F.
    Roosen, A.
    UROLOGE, 2014, 53 (03): : 391 - 399
  • [12] Steroidogenesis in castration-resistant prostate cancer
    Shiota, Masaki
    Endo, Satoshi
    Blas, Leandro
    Fujimoto, Naohiro
    Eto, Masatoshi
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2023, 41 (05) : 240 - 251
  • [13] Cabazitaxel for castration-resistant prostate cancer
    Shigeta, Keisuke
    Miura, Yuji
    Naito, Yoichi
    Takano, Toshimi
    LANCET, 2011, 377 (9760): : 121 - 121
  • [14] Enzalutamide in castration-resistant prostate cancer
    Burki, Talha Khan
    LANCET ONCOLOGY, 2014, 15 (08): : E312 - E312
  • [15] Denosumab in castration-resistant prostate cancer
    Kyrgidis, Athanassios
    Tzellos, Thrasivoulos-George
    LANCET, 2012, 379 (9828): : E50 - E50
  • [16] Corticotherapy in castration-resistant prostate cancer
    Lebdai, S.
    Branchereau, J.
    Robert, G.
    De La Tallie, A.
    Bouchaert, P.
    PROGRES EN UROLOGIE, 2013, 23 : S23 - S33
  • [17] Enzalutamide in Castration-Resistant Prostate Cancer
    Anker, Markus S.
    Lehmann, Lorenz H.
    Anker, Stefan D.
    NEW ENGLAND JOURNAL OF MEDICINE, 2018, 379 (14): : 1380 - 1380
  • [18] Nonmetastatic Castration-Resistant Prostate Cancer
    Hong, Jun Hyuk
    Kim, Isaac Y.
    KOREAN JOURNAL OF UROLOGY, 2014, 55 (03) : 153 - 160
  • [19] Metabolic syndrome in castration-resistant prostate cancer patients treated with abiraterone
    Conteduca, Vincenza
    Caffo, Orazio
    Derosa, Lisa
    Veccia, Antonello
    Petracci, Elisabetta
    Chiuri, Vincenzo Emanuele
    Santoni, Matteo
    Santini, Daniele
    Fratino, Lucia
    Maines, Francesca
    Testoni, Sara
    De Giorgi, Ugo
    PROSTATE, 2015, 75 (12): : 1329 - 1338
  • [20] Relationship between epigenetic and metabolic alterations in castration-resistant prostate cancer
    Kanesaka, Manato
    Sato, Hiroaki
    Hoshii, Takayuki
    Okabe, Atsushi
    Fukuyo, Masaki
    Nawai, Bahityar R.
    Sakamoto, Shinichi
    Komiya, Akira
    Ichikawa, Tomohiko
    Kaneda, Atsushi
    CANCER SCIENCE, 2022, 113 : 1592 - 1592